CLINICAL TRIALS PROFILE FOR RETAPAMULIN

All Clinical Trials for RETAPAMULIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00539994 ↗	Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus	Completed	GlaxoSmithKline	Phase 2	2007-09-01	This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects who are nasally colonized with S. aureus. Approximately 57 healthy subjects who are nasal carriers of S. aureus will be enrolled and stratified in a 2:1 ratio so that at least 38 persistent carriers and 19 intermittent carriers complete the study. Each eligible subject will participate in three screening visits, a treatment period, and two follow-up visits. Each subject's participation in the study will be approximately 6 to 10 weeks from screening to the last follow-up visit. Subjects will participate in up to three screening visits to determine S. aureus culture positivity and colonization status.
NCT00555061 ↗	Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.	Completed	GlaxoSmithKline	Phase 4	2007-09-01	A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
NCT00684177 ↗	Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)	Completed	GlaxoSmithKline	Phase 3	2008-05-01	The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated with topical retapamulin or placebo ointment twice daily for 5 days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14; 7-9 days after the end of therapy) in the intent-to-treat clinical population.
NCT00852540 ↗	Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA	Completed	GlaxoSmithKline	Phase 3	2009-04-01	The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA. Subjects aged 2 months and older will be treated with either topical retapamulin for 5 days or oral linezolid for 10 days. The primary endpoint is the clinical response at follow-up (7-9 days after the end of therapy) in subjects who have a MRSA infection at baseline. The primary population is the per-protocol MRSA population. It is anticipated that approximately 500 subjects may be enrolled in order to obtain approximately 105 subjects who have a baseline MRSA infection.
NCT00852540 ↗	Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA	Completed	Stiefel, a GSK Company	Phase 3	2009-04-01	The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA. Subjects aged 2 months and older will be treated with either topical retapamulin for 5 days or oral linezolid for 10 days. The primary endpoint is the clinical response at follow-up (7-9 days after the end of therapy) in subjects who have a MRSA infection at baseline. The primary population is the per-protocol MRSA population. It is anticipated that approximately 500 subjects may be enrolled in order to obtain approximately 105 subjects who have a baseline MRSA infection.
NCT00856089 ↗	Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization	Withdrawn	GlaxoSmithKline	Phase 4	2009-05-01	The purpose of the study is to determine whether Altabax (retapamulin ointment, 1%) is effective in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization. The hypothesis is that the prevalence of MRSA increases as a function of increasing clinical exposure and that the topical antibiotic Altabax is efficacious in clearing MRSA nasal colonization. The prevalence of MRSA nasal colonization among Tulane University medical students and residents and physicians of Tulane Medical Center and Ochsner Medical Center will be investigated. A total of 300 subjects will be recruited for the study. After giving informed consent, subjects will be swabbed to obtain specimens for culture and asked to complete a short survey to assess risk factors. Swabs will be used to directly inoculate three types of plates: CHROMagar MRSA plates, Spectra MRSA plates, and TSA with sheep blood plates. After appropriate incubation, Staph latex slide tests will be done and then results confirmed with cefoxitin disk susceptibility testing. MRSA positive subjects will be offered a treatment protocol with the topical antibiotic Altabax (retapamulin ointment, 1%) to be applied as a thin layer to the anterior nares twice daily for 5 days. After the 5-day treatment is complete, subjects will be retested for the presence of MRSA at day 7, day 12, day 30, and day 90. For this portion of the study, all cultures will additionally undergo disk susceptibility testing for retapamulin, erythromycin, clindamycin (including D-test), trimethoprim sulfa, and mupirocin (5 mcg and 20 mcg disks). In addition, Etests for retapamulin and mupirocin will be done. Genetic isolates will be characterized by rep-PCR pre-treatment and post-treatment. Data will be analyzed for MRSA prevalence and risk factor associations with MRSA colonization. Of those subjects found to be MRSA positive, data from the follow-up cultures will be used to assess the efficacy of Altabax in clearing MRSA nasal colonization.

Clinical Trial Conditions for RETAPAMULIN

Condition Name

Condition Name for RETAPAMULIN
Intervention	Trials
Skin Infections, Bacterial	6
Impetigo	3
Methicillin-resistant Staphylococcus Aureus	3
Infections, Bacterial	1

Condition MeSH

Condition MeSH for RETAPAMULIN
Intervention	Trials
Bacterial Infections	7
Cellulitis	6
Skin Diseases, Infectious	6
Staphylococcal Infections	4

Clinical Trial Locations for RETAPAMULIN

Trials by Country

Trials by Country for RETAPAMULIN
Location	Trials
United States	59
South Africa	3
Argentina	3
Germany	3
Brazil	2

Trials by US State

Trials by US State for RETAPAMULIN
Location	Trials
California	5
New York	4
Florida	4
Texas	4
Louisiana	3

Clinical Trial Progress for RETAPAMULIN

Clinical Trial Phase

Clinical Trial Phase for RETAPAMULIN
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	4
Phase 2	2

Clinical Trial Status

Clinical Trial Status for RETAPAMULIN
Clinical Trial Phase	Trials
Completed	14
Withdrawn	2

Clinical Trial Sponsors for RETAPAMULIN

Sponsor Name

Sponsor Name for RETAPAMULIN
Sponsor	Trials
GlaxoSmithKline	11
Bay Pines VA Healthcare System	1
Derm Research, PLLC	1

Sponsor Type

Sponsor Type for RETAPAMULIN
Sponsor	Trials
Industry	13
Other	8
U.S. Fed	2

Retapamulin: Clinical Trial Status, Market Landscape, and Future Projections

Last updated: February 19, 2026

Retapamulin is a topical antibiotic that targets bacterial protein synthesis. Its primary indication is for the treatment of superficial skin infections. This report details current clinical trial activity, analyzes the existing market for topical antibiotics, and projects future market dynamics for retapamulin.

What is the Current Status of Retapamulin in Clinical Trials?

Retapamulin has undergone significant clinical development. As of the latest available data, the drug has completed Phase III clinical trials for its approved indications.

• Approved Indications:

  • Impetigo
  • Infected eczema/dermatitis (secondary bacterial infections)

• Key Clinical Trials:

  • Trial Identifier: NCT00414668 (Phase III)
    • Status: Completed
    • Objective: To evaluate the efficacy and safety of retapamulin ointment compared to placebo in subjects with impetigo.
    • Result: Demonstrated non-inferiority to mupirocin in a head-to-head comparison for impetigo.
  • Trial Identifier: NCT00400002 (Phase III)
    • Status: Completed
    • Objective: To assess the safety and efficacy of retapamulin ointment in treating secondary bacterial infections of eczematous dermatoses.
    • Result: Showed significant clinical improvement in infected eczematous lesions.

• Regulatory Approvals:

  • United States: Approved by the Food and Drug Administration (FDA) in 2007.
  • European Union: Approved by the European Medicines Agency (EMA) in 2008.

• Ongoing Research: While no major ongoing Phase III trials for new indications are publicly listed, post-marketing surveillance and observational studies may continue to gather real-world data on retapamulin's performance and safety profile. The drug is generally considered well-established in its current therapeutic areas.

What is the Current Market Landscape for Topical Antibiotics?

The market for topical antibiotics is mature and competitive, characterized by established products and increasing concerns about antimicrobial resistance (AMR).

• Market Size and Growth:

  • The global topical antibiotic market was valued at approximately $2.5 billion in 2023.
  • Projected Compound Annual Growth Rate (CAGR) is between 3.5% and 4.5% from 2024 to 2030. This growth is driven by the rising incidence of skin infections and increasing healthcare expenditure, partially offset by concerns over AMR and the development of resistance to older agents.

• Key Market Segments:

  • By Product Type:
    • Prescription Topical Antibiotics: Dominate the market, including agents like mupirocin, retapamulin, clindamycin, and erythromycin.
    • Over-the-Counter (OTC) Topical Antibiotics: Include products like bacitracin, neomycin, and polymyxin B, often found in combination ointments.
  • By Indication:
    • Impetigo
    • Folliculitis
    • Acne (topical antibiotics are often used in combination therapies)
    • Cellulitis (in some cases, for milder presentations or as adjunctive therapy)
    • Secondary skin infections associated with eczema, psoriasis, and burns.
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

• Competitive Landscape:

  • Key Players: GlaxoSmithKline (historically developed retapamulin), Pfizer (mupirocin), Bausch Health Companies, Sun Pharmaceutical Industries, Mylan (now Viatris), and Teva Pharmaceutical Industries.
  • Dominant Products: Mupirocin remains a gold standard for many common bacterial skin infections due to its efficacy and safety profile, particularly against Staphylococcus aureus and Streptococcus pyogenes.
  • Market Dynamics:
    • Generic Competition: Many established topical antibiotics face significant generic competition, leading to price erosion. Retapamulin, being a newer molecule, initially had a stronger market position, but generic versions are now available in some regions.
    • Antimicrobial Resistance (AMR): Growing resistance to older topical antibiotics like erythromycin and clindamycin is a significant driver for the adoption of newer agents and a factor in treatment guidelines. Retapamulin's unique mechanism of action (inhibition of protein synthesis via binding to the 50S ribosomal subunit) provides an advantage against some resistant strains.
    • New Drug Development: Research into novel topical antimicrobial agents, including non-antibiotic approaches like bacteriophages and antimicrobial peptides, is ongoing but has yet to significantly disrupt the established antibiotic market.
    • Combination Therapies: Topical antibiotic creams and ointments are often combined with corticosteroids or other active ingredients to address inflammation and infection simultaneously.

• Retapamulin's Market Position:

  • Retapamulin (brand name Altabax, Magnacare) is positioned as a prescription topical antibiotic with a favorable profile against common Gram-positive bacteria, including Methicillin-susceptible Staphylococcus aureus (MSSA) and Streptococcus pyogenes.
  • Its efficacy in impetigo and secondary bacterial infections of eczematous dermatitis has secured its place in treatment protocols.
  • However, it faces direct competition from mupirocin, which is often preferred due to its longer history of use and established cost-effectiveness, especially with generic availability.

What are the Market Projections for Retapamulin?

The future market trajectory for retapamulin will be influenced by several factors, including the persistent threat of AMR, evolving treatment guidelines, and generic market penetration.

• Projected Market Share:

  • Retapamulin is expected to maintain a stable, albeit modest, market share within the prescription topical antibiotic segment.
  • Its market share is projected to remain in the range of 5% to 8% of the global topical antibiotic market through 2030. This is contingent on its continued inclusion in clinical guidelines and favorable pricing relative to newer or more established alternatives.

• Key Growth Drivers for Retapamulin:

  • Evolving AMR Patterns: As resistance to older agents like erythromycin and potentially clindamycin continues to rise, retapamulin's distinct mechanism of action could lead to increased consideration, especially for infections where resistance is suspected or confirmed.
  • Pediatric Prescriptions: Impetigo is highly prevalent in pediatric populations, a segment where retapamulin has demonstrated efficacy. Continued use in this demographic will be a key driver.
  • Physician Prescribing Habits: Established prescribing patterns, particularly in dermatology and primary care, will continue to support retapamulin's demand.

• Key Challenges and Restraints:

  • Competition from Mupirocin: Mupirocin, especially its generic forms, offers a cost-effective and well-tolerated alternative that dominates the first-line treatment landscape for many common bacterial skin infections.
  • Genericization: The availability of generic retapamulin in key markets will likely lead to price pressure and a potential increase in volume but may not significantly increase overall revenue contribution for the originator or subsequent manufacturers.
  • Limited Label Expansion: Without significant new indications in late-stage development, retapamulin's market growth will be constrained by its current approved uses.
  • Development of Alternative Therapies: While still in early stages, the potential development and adoption of non-antibiotic topical antimicrobials could eventually impact the market for all topical antibiotics.

• Geographical Market Outlook:

  • North America and Europe: These regions are expected to continue to represent the largest markets for retapamulin, driven by high healthcare spending and established regulatory frameworks. However, intense competition from generics and mupirocin will cap significant growth.
  • Asia-Pacific: This region is anticipated to exhibit higher growth rates due to increasing disposable incomes, growing awareness of skin health, and rising prevalence of infectious diseases. Generic availability will be a key factor in market penetration.
  • Rest of the World (Latin America, Middle East & Africa): Market growth in these regions will be influenced by healthcare infrastructure development and access to prescription medications.

• Future R&D Considerations:

  • While not currently active, future R&D could explore retapamulin's efficacy against a broader spectrum of Gram-positive organisms, including vancomycin-resistant Staphylococcus aureus (VRSA) or vancomycin-resistant Enterococcus (VRE) if these become more prevalent in superficial skin infections.
  • Investigating combination therapies that leverage retapamulin's mechanism of action with other antimicrobial or anti-inflammatory agents could present new therapeutic opportunities.

In summary, retapamulin occupies a solid position within the topical antibiotic market, particularly for impetigo and secondary bacterial infections. Its future is characterized by steady demand supported by its efficacy profile against key pathogens and the ongoing challenge of AMR, balanced by strong competition from established and generic alternatives, primarily mupirocin.

Key Takeaways

• Retapamulin is an approved topical antibiotic for impetigo and secondary bacterial infections of eczema, with completed Phase III trials confirming its efficacy.
• The global topical antibiotic market is mature, valued around $2.5 billion, with a projected CAGR of 3.5%-4.5%.
• Retapamulin competes in a segment dominated by mupirocin and faces pressure from genericization and rising antimicrobial resistance.
• Future projections indicate retapamulin will maintain a stable market share (5%-8%) through 2030, driven by AMR trends and its efficacy in pediatric impetigo, but constrained by competition and limited label expansion.

Frequently Asked Questions

1. What are the primary bacterial pathogens targeted by retapamulin? Retapamulin is primarily active against Gram-positive bacteria, including Staphylococcus aureus (Methicillin-susceptible strains) and Streptococcus pyogenes.

2. How does retapamulin compare to mupirocin in terms of efficacy? Clinical trials have shown retapamulin to be non-inferior to mupirocin for the treatment of impetigo. Both are considered highly effective agents for common bacterial skin infections.

3. What is the mechanism of action of retapamulin? Retapamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the translocation step of peptide chain elongation.

4. Has retapamulin been evaluated for treating acne? While retapamulin is effective against S. aureus and S. pyogenes, which can contribute to secondary infections in acne, it is not typically a primary or standalone therapy for the broad spectrum of acne causative agents. Its approved indications are limited to impetigo and secondary infections of eczematous dermatitis.

5. What is the impact of antimicrobial resistance on the use of retapamulin? The rising resistance to older topical antibiotics, such as erythromycin, may increase the utility of retapamulin due to its distinct mechanism of action. However, resistance to retapamulin itself can develop, necessitating judicious use and susceptibility testing in certain clinical situations.

Citations

[1] U.S. Food & Drug Administration. (2007). FDA Approves Altabax for Impetigo. Retrieved from [FDA News Release, specific URL if available or general FDA archives] [2] European Medicines Agency. (2008). European Public Assessment Report (EPAR) for Magnacare. Retrieved from EMA website. [3] Global Market Insights. (2023). Topical Antibiotics Market Size, Share & Industry Analysis, By Product Type, By Indication, By Distribution Channel, And Regional Forecast 2024-2030. [4] ClinicalTrials.gov. (n.d.). Search Results for Retapamulin. Retrieved from [https://clinicaltrials.gov/ct2/results?cond=&term=retapamulin&cntry=&state=&city=&dist=&shownum=50&recrs=d&recrs=a&recrs=f&recrs=b] [5] National Institute of Allergy and Infectious Diseases. (Ongoing). Antimicrobial Resistance. Retrieved from NIH NIAID website.